Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Metadata
Title
MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer
Authors
Paul J. Cozzi
Jian Wang
Warick Delprado
Alan C. Perkins
Barry J. Allen
Pamela J. Russell
Yong Li
Publication date
01-11-2005
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 7/2005
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-005-5376-z

Other articles of this Issue 7/2005

Clinical & Experimental Metastasis 7/2005 Go to the issue

OriginalPaper

Transforming Growth Factor-β1 Upregulates Transcription of α3 Integrin Gene in Hepatocellular Carcinoma Cells Via Ets-transcription Factor-binding Motif in the Promoter Region

OriginalPaper

Metastatic Progression of Pancreatic Cancer: Changes in Antioxidant Enzymes and Cell Growth

OriginalPaper

Low-dose Methotrexate Inhibits Lung Metastasis and Lengthens Survival in Rat Osteosarcoma

OriginalPaper

Chromosomal Alterations in Lung Metastases of Colorectal Carcinomas: Associations with Tissue Specific Tumor Dissemination

OriginalPaper

Metastasis Predictive Signature Profiles Pre-exist in Normal Tissues

OriginalPaper

Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits